The performance of a hemostatic agent based on oxidized regenerated cellulose - polyglactin 910 composite in a liver defect model in immunocompetent and athymic rats

Biomaterials

Volumn 31, Issue 13, 2010, Pages 3649-3656

  Muench, Tim R ^a   Kong, Wei ^a   Harmon, Alex M ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

Animal model; Biocompatibility; Fibrinogen; Hemostasis; Immune response; Thrombin

Indexed keywords

ANIMAL MODEL; ATHYMIC; CLINICAL SETTINGS; CLINICAL SITUATIONS; DEFECT MODEL; HEMOSTATIC AGENTS; IMMUNE RESPONSE; MATERIAL ABSORPTION; MATRIX; OXIDIZED REGENERATED CELLULOSE; POLYGLACTIN; POST-IMPLANTATION; PRE-CLINICAL; REGULATORY CONSIDERATIONS; SURGICAL FIELD; SURGICAL METHOD; TREATMENT MODALITY;

ABSORPTION; ANIMALS; DEFECTS; DEGRADATION; IMMUNOLOGY; LIVER; RATS;

BIOCOMPATIBILITY;

CELLULOSE; FIBRIN; HEMOSTATIC AGENT; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; COMPOSITE MATERIAL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMPLANTATION; LIVER DISEASE; MALE; NONHUMAN; NUDE RAT; OXIDATION; PRIORITY JOURNAL; RAT;

ANIMALS; CELLULOSE; HEMOSTATICS; IMMUNITY, CELLULAR; IMMUNOCOMPETENCE; LIVER; OXIDATION-REDUCTION; POLYGLACTIN 910; RATS; RATS, NUDE;

ANIMALIA; RATTUS;

EID: 77249118675     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.01.070     Document Type: Article

References (14)

1. Maisano F., Kjaergård H.K., Bauernschmitt R., Pavie A., Rábago G., Laskar M., et al. TachoSil surgical patch versus conventional haemostatic fleece material for control of bleeding in cardiovascular surgery: a randomized controlled trial. Eur J Cardiothorac Surg 36 4 (2009) 708-714
2. Lomax C., and Traub O. Topical thrombins: benefits and risks. Pharmacotherapy 29 7 Pt 2 (2009) 8S-12S
3. Rickenbacher A., Breitenstein S., Lesurtel M., and Frilling A. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery - a systematic review. Expert Opin Biol Ther 9 7 (2009) 897-907
4. Tomizawa Y. Clinical benefits and risk analysis of topical hemostats: a review. J Artif Organs 8 3 (2005) 137-142
5. Boucher B.A., and Traub O. Achieving hemostasis in the surgical field. Pharmacotherapy 29 7 Pt 2 (2009) 2S-7S
6. Dalpiaz O., Neururer R., Bartsch G., and Peschel R. Haemostatic sealants in nephron-sparing surgery: what surgeons need to know. BJU Int 102 11 (2008) 1502-1508
7. Wheat J.C., and Wolf Jr. J.S. Advances in bioadhesives, tissue sealants, and hemostatic agents. Urol Clin North Am 36 2 (2009 May) 265-275
8. European Medicines Agency Evaluation of Medicines for Human Use. Assessment report for Evicel. Procedure No. EMEA/H/C000898. Doc. Ref. EMEA/CHMP/449199/2008.
9. Levy B. Topical hemostasis agents: some tried and true, others too new. OBG Manage 20 9 (2008) 31-38
10. Naoum J.J. Immune-mediated coagulopathy: a case report. Pharmacotherapy 29 7 Pt 2 (2009) 13S-17S
11. ISO 10993-6 Biological Evaluation of Medical Devices (2007): Tests for local effects after implantation.
12. Rolstad B. The athymic nude rat: an animal experimental model to reveal novel aspects of innate immune responses?. Immunol Rev 184 (2001) 136-144
13. Tanaka K.A., Key N.S., and Levy J.H. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 108 5 (2009) 1433-1446
14. Mosier D.A. Vacsular disorders and thrombosis. In: McGavin M.D., and Zachary J.F. (Eds). Pathologic basis of veterinary disease. 4th ed (2007), Morsby, St. Louis 73-82